Main menu

Pages

Slone Partners Names Doug Lawrence Chief Executive Officer of Hygieia

“Doug Lawrence is an exceptionally ambitious and accomplished diabetes technology leader with a track record of tremendous success leading global business operations.

Slone Partners, a national executive search firm for life sciences, biotech and healthcare companies, announces the appointment of Doug Lawrence as CEO of Hygieia, a leading digital therapeutics company in insulin therapy . He leads the operations, development and global growth of the company and its d-Nav® insulin management program.

Lawrence brings 30 years of medical technology leadership at Hygieia to his new role at Hygieia. This includes significant experience in introducing products to the market, restructuring and leading companies through mergers and acquisitions, building global sales teams, raising venture capital and overseeing operations. A seasoned CEO, Lawrence has led three of his companies, including CeQur, a company that manufactures insulin patch pumps to treat type 2 diabetes. He also headed the diabetes division at He Becton Dickinson (now He Embecta), a leading manufacturer of insulin syringes and pen needles.

“Doug Lawrence is an exceptionally ambitious and accomplished diabetes technology leader with a track record of tremendous success leading global business operations. I am well positioned to bring my knowledge to Hygieia and move the company forward.”

Dr. Eran Bashan, Co-Founder and Chairman of the Board of Hygieia, said: “Now with Doug as CEO, we will work together to build the nation’s leading network of diabetes clinics. We look forward to partnering with others to simplify insulin therapy and improve outcomes.”

Lawrence holds a Bachelor of Science in Engineering (BSE) from the Jerome Fisher Program in Business and Technology at the University of Pennsylvania and a Master of Business Administration (MBA) in Marketing from the Kellogg School of Management at Northwestern University.

About Sloan Partners

Slone Partners provides leaders to build People Are Our Science®, an amazingly diverse life sciences and healthcare organization. Founded in 2000, Slone Partners brings world-class executives, executives and senior management to some of the most promising and established biotechnology, diagnostics, research tools, healthcare, precision medicine, medical device and laboratory services companies. We specialize in providing human resources. With domestic and international clients, Slone Partners uniquely and accurately delivers a suite of executive search and advisory services, including diversity, equity and inclusion strategies, to innovative life sciences and healthcare companies. For more information on the Slone Partners value proposition and process, please visit http://www.slonepartners.com or call 888.784.3422.

About Hygeia

Hygieia is the developer of d-Nav®. d-Nav® is the first FDA-cleared technology to autonomously adjust insulin doses to patients. Her AI-powered technology in d-Nav automatically interprets patient data and initiates insulin management on an individual basis. The d-Nav Insulin Management Program adds clinical support to help people with type 2 diabetes adjust their insulin dosage according to the body’s changing insulin needs. Studies have shown that nearly 90% of those using d-Nav reported that his A1C decreased in just 3 months without increasing the risk of hypoglycemia**. The d-Nav Insulin Management Program has been peer-reviewed with research published in leading medical journals. Hygieia is headquartered in Livonia, Michigan. For more information, please visit d-Nav.com.

*John E. Schneider et al Impact of new insulin administration services on non-insulin drug costs. J Health Econ Outcomes Res. 20 Feb 2018;6(1):53-62. https://jheor.org/article/9783

**Richard M Bergenstal et al. Automatic insulin dosing guidance for optimizing insulin management in people with type 2 diabetes: a multicenter randomized controlled trial. Lancet Mar 16, 2019;393(10176):1138-1148. https://pubmed.ncbi.nlm.nih.gov/30808512/

Share articles on social media or email:

.

Comments